Immunotherapy of Urological Tumours

Part 1 Intravesical therapy with Bacillus Calmette-Guerin: Bacillus Calmette-Guerin immunotherapy in bladder cancer, N.Netto Jr and C.D'Ancona; immunotherapy (BCG) versus chemotherapy (MMC) in intravesical treatment of superficial urinary bladder cancer, K.Jauhiainen et al; prospective randomized study of adjuvant therapy after complete resection of superficial bladder cancer; mitomycin C vs BCG Connaught v Tur alone, H.Rubben et al; five-year follow-up of bladder tumours treated with BCG, O.Gogus et al; prevention of recurrence of superficial bladder cancer with BCG, S.Vildosola et al; the significance of tumour histology in the results of treatment with intravesical BCG for superficial bladder cancer, H.Winkler et al; intravesical BCG for superficial bladder cancer - comparison of results on primary tumour to development of progressive disease elsewhere, J.D.Schmidt; BCG vs doxorubicin v thiotepa instillation for primary superficial bladder cancer, interim report of a randomized prospective study, J.A.Martinez-Pineiro et al; low-dose BCG therapy in superficial bladder cancer - a clinicopathological prospective study, F.Pagano et al; effects of local BCG therapy in patients with bladder carcinoma on phenotypes and function of mononuclear cells, A.Bohle et al; intravesical BCG therapy in patients with superficial bladder cancer, A.Steg et al; analysis and commentary - intravesical therapy with BCG, J.B.de Kernion. Part 2 Other intravesical agents: intravesical alpha-interferon in the treatment of superficial bladder cancer, R.D.Williams; intravesical instillation therapy using interferon for treatment of bladder cancer, M.Hara et al; immunotherapy with keyhole-limpet haemocyanin (KLH) as prophylaxis against superficial bladder tumour recurrence, C.Jurincic et al; pilot study on the effects of peritumoral and intranodal injection of low doses of interferon-gamma in patients with recurrent superficial bladder carcinoma, G.Fontana et al; the prevention of recurrence of superficial bladder tumours with immunochemotherapy, K.Matsumoto et al; analysis and commentary - other intravesical agents, J.B.de Kernion. Part 3 Immunotherapy of renal cell carcinoma: combination therapy with recombinant interferon-alpha and -gamma in advanced renal cell carcinoma-a phase 1-11 study, M.P.H.Franssen et al; biologic response modifier therapy of metastatic renal cell carcinoma - the UCLA experience, R.Figlin et al; human lymphoblastoid interferon treatment of metastatic renal cell carcinoma, T.Kawai et al; long-term interferon treatment in metastatic renal cell carcinoma, W.Levens et al; adjunctive interferon treatment in non-metastatic renal cell carcinoma, W.Levens et al. (Part contents)